KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Cash & Equivalents (2018 - 2026)

Takeda Pharmaceutical has reported Cash & Equivalents over the past 9 years, most recently at $3.8 billion for Q1 2026.

  • For Q1 2026, Cash & Equivalents rose 50.32% year-over-year to $3.8 billion; the TTM value through Mar 2026 reached $3.8 billion, up 50.32%, while the annual FY2026 figure was $4.0 billion, 56.36% up from the prior year.
  • Cash & Equivalents was $3.8 billion for Q1 2026 at Takeda Pharmaceutical, up from $2.5 billion in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $7.3 billion in Q1 2022 and bottomed at $2.5 billion in Q1 2025.
  • The 5-year median for Cash & Equivalents is $3.8 billion (2026), against an average of $4.2 billion.
  • Year-over-year, Cash & Equivalents crashed 44.83% in 2023 and then soared 50.32% in 2026.
  • Over 5 years, Cash & Equivalents stood at $7.3 billion in 2022, then crashed by 44.83% to $4.0 billion in 2023, then fell by 23.41% to $3.1 billion in 2024, then dropped by 18.29% to $2.5 billion in 2025, then soared by 50.32% to $3.8 billion in 2026.
  • The last three reported values for Cash & Equivalents were $3.8 billion (Q1 2026), $2.5 billion (Q1 2025), and $3.1 billion (Q1 2024) per Business Quant data.